Clinical trial · Observational
Study of Tumor and Blood Samples From Women With Breast Cancer
Colon and Breast Cancer Diagnostics. Clinical Protocol Associated With Cancer of the Breast.
NCT00897728CI-TRIAL-00004155unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. PURPOSE: This research study is looking at tumor and blood samples from women with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| laboratory biomarker analysis | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Local or remote relapse as assessed by biomarkers in tissue and blood samples collected during the first 2 years after diagnosis
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS: * Diagnosis of infiltrating unilateral breast cancer * No in situ disease (ductal or lobular) * No invasive bilateral synchronous disease * Breast cancer at high risk, defined by at least 2 of the following factors: * Hormone receptor negative (HR-) * Axillary node positive * Histopathologic grade III * High mitotic index (as defined by the Curie Institute as \> 20 mitoses per 10 high-power fields \[HPF\]) * Tumor size ≥ 2 cm * HER2-positive (3 + IHC or FISH/ICHS positive) * Triple-negative tumors (HR- and HER2-negative) * Initial thoracic-abdomino-pelvic and bone scans must be negative * Underwent initial surgery PATIENT CHARACTERISTICS: * Menopausal status not specified * Serum calcium normal (15.3 mg/dL) or normalized within 8 weeks after surgery * No other invasive cancer within the past 5 years * Not pregnant or nursing * No psychological, familial, social, or geographical reasons that make monitoring impossible PRIOR CONCURRENT THERAPY: * See Disease Characteristics
References
Publications (0)
Data not yet available
No reference posted for this study.